• Idorsia entered a co-development and commercialization agreement with Nxera Pharma for lucerastat, its investigational Fabry disease treatment.
• Nxera will pay CHF 7 million following exercise of its option and contribute to the global Phase 3 program.
• The deal grants Nxera exclusive development and commercialization rights in Japan and selected Asia-Pacific territories, excluding China.
• Royalties on net sales in the licensed territories remain payable to Idorsia.
• The Phase 3 program includes the newly initiated FAB-KLEAR study and could support a regulatory filing as early as 2029.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Idorsia Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280200OMX_____CNEWS_EN_GNW1001280266_en) on October 28, 2026, and is solely responsible for the information contained therein.